# A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

> **NCT01172392** · PHASE3 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 185 (actual)

## Conditions studied

- Chronic Hepatitis B
- AgHbs Negativation

## Interventions

- **DRUG:** Pegylated interferon-alpha-2a
- **DRUG:** Nucleotidic or Nucleosidic Treatment

## Key facts

- **NCT ID:** NCT01172392
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2013-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01172392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01172392, "A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01172392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*